The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Abstract
PURPOSE: The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic non–small-cell lung cancer (NSCLC), the response rate was 33%, with a median survival of 8.4 months. Based on such favorable results, the Hoosier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared with cisplatin alone in chemotherapy-naive patients with advanced NSCLC. PATIENTS AND METHODS: Patients were randomized to receive either cisplatin (100 mg/m 2 intravenously on day 1 of a 28-day cycle) or the combination of cisplatin (100 mg/m 2 intravenously on day 1) plus gemcitabine (1,000 mg/m 2 administered intravenously on days 1, 8, and 15 of a 28-day cycle). RESULTS: From August 1995 to February 1997, 522 assessable chemotherapy-naive patients were randomized. Toxicity was predominantly hematologic and was more pronounced in the combination arm, with grade 4 neutropenia occurring in 35.3% of patients compared with 1.2% of patients on the cisplatin monotherapy arm. The incidence of neutropenic fevers was less than 5% in both arms. Grade 4 thrombocytopenia occurred in 25.4% of patients on the combination arm compared with 0.8% of patients on the cisplatin monotherapy arm. No serious hemorrhagic events related to thrombocytopenia were reported for either arm. The combination of gemcitabine plus cisplatin demonstrated a significant improvement over single-agent cisplatin with regard to response rate (30.4% compared with 11.1%, respectively; P < .0001), median time to progressive disease (5.6 months compared with 3.7 months, respectively; P = .0013), and overall survival (9.1 months compared with 7.6 months, respectively; P = .004). CONCLUSIONS: For the first-line treatment of NSCLC, the regimen of gemcitabine plus cisplatin is superior to cisplatin alone in terms of response rate, time to disease progression, and overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Le Chevalier, T., Brisgand, D., Douillard, J. Y., Pujol, J. L., Alberola, V, Monnier, A., Riviere, A., Lianes, P., Chomy, P., & Cigolari, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.360 · Cited by 811
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Rapp, E., Pater, J. L., Willan, A., Cormier, Y., Murray, N., Evans, W. K., Hodson, D. I., Clark, D. A., Feld, R., & Arnold, A. M. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.633 · Cited by 698
Self-citationWozniak, A. J., Crowley, J. J., Balcerzak, S. P., Weiss, G. R., Spiridonidis, C. H., Baker, L. H., Albain, K. S., Kelly, K., Taylor, S. A., Gandara, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2459 · Cited by 555
Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosides
Hertel, L. W., Kroin, J. S., Misner, J. W., & Tustin, J. M. (1988) · The Journal of Organic Chemistry · doi:10.1021/jo00246a002 · Cited by 366
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., & Rugg, T. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1535 · Cited by 359
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Crinò, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.297 · Cited by 303
Ganz, P. A., Figlin, R. A., Haskell, C. M., la Soto, N., Siau, J., & For the UCLA Solid Tumor Study Group (1989) · Cancer · doi:10.1002/1097-0142(19890401)63:7<1271::aid-cncr2820630707>3.0.co;2-6 · Cited by 206
Abratt, R. P., Bezwoda, W. R., Goedhals, L., & Hacking, D. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.744 · Cited by 177
Woods, R., Williams, C., Levi, J. A., Page, J., Bell, D., Byrne, M., & Kerestes, Z. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.135 · Cited by 155
Gandara, D. R., Crowley, J. J., Livingston, R. B., Perez, E. A., Taylor, C. W., Weiss, G. R., Neefe, J. R., Hutchins, L. F., Roach, R. W., & Grunberg, S. M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.5.873 · Cited by 150
Cellerino, R., Tummarello, D., Guidi, F., Isidori, P., Raspugli, M., Biscottini, B., & Fatati, G. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.8.1453 · Cited by 132
Klastersky, J. A., Sculier, J., Bureau, G., Libert, P., Ravez, P., Vandermoten, G., Thiriaux, J., Lecomte, J., Cordier, R., & Dabouis, G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1087 · Cited by 130
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90260-q · Cited by 125
Quoix, É., Dietemann, A., Charbonneau, J., Boutin, C., Meurice, J.-C., Orlando, J.-P., Ducoloné, A., Pauli, G., & Roegel, E. (1991) · PubMed · Cited by 61
Cited by
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Self-citationPfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Multidisciplinary Management of Lung Cancer
Spira, A., & Ettinger, D. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035536 · Cited by 922
Metadata
- Authors
- Sandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., Nguyen, B., Niyikiza, C., & Einhorn, L. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-01-01
- Volume
- 18
- Issue
- 1
- Pages
- 122-122
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1848316250
- Cited by
- 712
- References
- 17
- FWCI
- 61.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.